Mary Struthers

This inventor holds 13 USPTO granted patents and 11 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2020-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mary Struthers. Retrieved from https://idiyas.com/inventor/mary-struthers

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 13 (Patent Applications = 11)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 1 (Patent Applications = 7)

Average Co-Inventor Count = 3.9

ph-index = 3

Forward Citations = 27(Granted Patents)

Company Filing History:

13 out of 3,745

Bristol-Myers Squibb Compnay

patents

Years Active: 2020-2026

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12767721 - CD40 Antagonist Antibody Variants with Improved Pharmacokinetic Properties (2026-10-20),

2. 12419953 - Methods of treatment or prevention of immune responses and inflammatory diseases with antagonistic CD40 monoclonal antibodies (2025-09-23),

3. 12409223 - Antagonistic CD40 monoclonal antibodies and uses thereof (2025-09-09),

4. 12202872 - Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use (2025-01-21),

5. 11926673 - Antagonistic CD40 monoclonal antibodies and uses thereof (2024-03-12),

6. 11795231 - Antagonistic CD40 monoclonal antibodies and uses thereof (2023-10-24),

7. 11773178 - Antagonistic CD40 monoclonal antibodies and uses thereof (2023-10-03),

8. 11613585 - Nucleic acids encoding antagonistic CD40 monoclonal antibodies (2023-03-28),

9. 11359000 - Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use (2022-06-14),

10. 11261258 - Antagonistic CD40 monoclonal antibodies and uses thereof (2022-03-01),

11. 11254750 - Antagonistic CD40 monoclonal antibodies and uses in treating immune responses (2022-02-22),

12. 11220550 - Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity (2022-01-11),

13. 10787494 - Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use (2020-09-29),

Title: Mary Struthers: Innovator in Immunology

Introduction

Mary Struthers is a prominent inventor based in Edison, NJ (US), known for her significant contributions to the field of immunology. With a total of 13 patents to her name, she has made remarkable strides in developing treatments for immune responses and inflammatory diseases.

Latest Patents

Among her latest patents are innovative methods for the treatment or prevention of immune responses and inflammatory diseases using antagonistic CD40 monoclonal antibodies. These patents disclose antibodies that bind to CD40, including humanized antibodies that do not exhibit CD40 agonist activity. The antibodies may feature a modified IgG1 Fc domain and show minimal activation of immature dendritic cells. Additionally, the patents provide compositions comprising these antibodies, methods for treating diseases involving CD40 activity, and their use in preparing medicaments for such treatments.

Career Highlights

Mary Struthers is currently associated with Bristol-Myers Squibb Company, where she continues to advance her research and development efforts. Her work has been instrumental in paving the way for new therapeutic approaches in immunology.

Collaborations

Throughout her career, Mary has collaborated with notable colleagues, including Stanley Richard Krystek, Jr. and Akbar Nayeem, contributing to a dynamic research environment that fosters innovation.

Conclusion

Mary Struthers exemplifies the spirit of innovation in the field of immunology, with her groundbreaking patents and collaborative efforts. Her work continues to impact the development of treatments for complex immune-related conditions.

Profile summary based on public USPTO records.